drugset
drugset / Trial / NCT05333029

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

NCT05333029 ↗

Phase 2 Withdrawn Molly Gallogly
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if two treatments (extracorporeal photopheresis and Mesenchymal Stromal Cell (MSC) infusion, can be given safely together, and if they improve the symptoms of a Graft versus Host Disease (GvHD), a complication that can occur in people who undergo stem cell transplant.

Timeline

Start
2024-10-01
Primary completion
2024-12-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 2e+06 cells/kg Intravenous

Indications

graft versus host disease